替格列司他在高尿酸血症痛风患者中的降血清尿酸疗效与安全性:一项随机、双盲、安慰剂对照、剂量探索试验
这项多中心II期随机双盲安慰剂对照平行组剂量探索试验纳入143例高尿酸血症痛风患者,评估每日口服替格列司他50 mg、100 mg或200 mg共12周的疗效与安全性。第12周血清尿酸<5.0 mg/dl的患者比例在50 mg组为47.1%、100 mg组为44.7%、200 mg组为62.2%,均显著高于安慰剂组的2.9%(P<0.0001)。替格列司他在所研究各剂量下均显著降低血清尿酸,安全性可接受。
要点
- 第12周血清尿酸<5.0 mg/dl比例:替格列司他50 mg组47.1%、100 mg组44.7%、200 mg组62.2%,安慰剂组2.9%(P<0.0001)。
- 替格列司他组血清尿酸较基线平均百分比变化为-38.8%至-61.8%,在所有时间点均显著大于安慰剂组(P<0.0001)。
- 不良事件发生率为50.0%至56.8%,严重程度为轻或中度;需挽救治疗的痛风发作率为9.4%至13.2%。
核心结论
- 替格列司他在所研究各剂量下均较安慰剂显著降低血清尿酸,且安全性可接受。
研究设计与样本
- 多中心、II期、随机、双盲、安慰剂对照、平行组、剂量探索试验。
- 经筛查并在适当洗脱后,高尿酸血症痛风患者随机接受每日口服替格列司他50 mg、100 mg或200 mg或安慰剂治疗12周。
- 所有患者均接受秋水仙碱痛风发作预防。
- 主要终点为第12周血清尿酸水平<5.0 mg/dl的患者比例。
- 共143例患者随机分组:替格列司他50 mg组(n=34)、100 mg组(n=38)、200 mg组(n=37)、安慰剂组(n=34)。
主要发现
- 第12周达到血清尿酸<5.0 mg/dl的患者比例:替格列司他50 mg组47.1%、100 mg组44.7%、200 mg组62.2%,安慰剂组2.9%(P<0.0001)。
- 替格列司他组血清尿酸较基线平均百分比变化为-38.8%至-61.8%,在所有时间点均显著大于安慰剂组(P<0.0001)。
- 需挽救治疗的痛风发作率在替格列司他组和安慰剂组为9.4%至13.2%。
- 所有组不良事件发生率为50.0%至56.8%,严重程度为轻或中度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the safety and efficacy of the nonpurine xanthine oxidase inhibitor tigulixostat for lowering serum urate level in gout patients with hyperuricemia. METHODS: We conducted a multicenter, phase II, randomized, double-blind, placebo-controlled, parallel-group, dose-finding trial. After screening, gout patients with hyperuricemia were randomly assigned, after appropriate washout, to receive daily oral administration of 50 mg, 100 mg, or 200 mg of tigulixostat, or placebo for 12 weeks. Colchicine gout flare prophylaxis was administered to all patients. The primary end point was the proportion of patients with a serum urate level <5.0 mg/dl at week 12. RESULTS: A total of 143 patients were randomized to receive tigulixostat 50 mg (n = 34), 100 mg (n = 38), or 200 mg (n = 37), or placebo (n = 34). A significantly greater proportion of patients in the tigulixostat groups achieved the target serum urate level <5.0 mg/dl at week 12 (47.1% in the 50 mg group, 44.7% in the 100 mg group, and 62.2% in the 200 mg group) compared to the placebo group (2.9%) (P < 0.0001). The mean percentage change in serum urate level from baseline was also significantly greater in the tigulixostat groups (-38.8% to -61.8%) than in the placebo group at all time points (P < 0.0001). The rate of gout flares requiring rescue treatment ranged from 9.4% to 13.2% in the tigulixostat and placebo groups. The incidence of adverse events was 50.0% to 56.8% across all groups, and their severity was mild or moderate. CONCLUSION: Tigulixostat significantly lowered serum urate compared to placebo at all doses studied with an acceptable safety profile.
引用
- Terkeltaub R, Lee J, Min J, et al. Serum Urate-Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial. Arthritis Rheumatol. 2023. PMID: 36649008. doi:10.1002/art.42447
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。